Advertisement
Advertisement
AKBA
Akebia Therapeutics, Inc.
1.90
USD-0.01
-0.78%
Mar 07, 15:55 UTC -5
Closed
After-Market
1.915
+0.02
+0.79%
Akebia Therapeutics, Inc. Profile
About
Info & Links
CEO
John P. Butler
Headquarters
CAMBRIDGE, MA 02142, UNITED STATES
Industry
Sector
Website
Auditor
Ernst & Young LLP
Share holders
30
Employees
167
Akebia Therapeutics, Inc. Statistics
Valuation Measures
Market Capitalization2
417.82M
Enterprise Value
422.15M
Enterprise Value/EBITDA(ttm)
152.40
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
2.45
Price to Book(mrq)
--
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
63.58%
Operating Margin(ttm)
-27.07%
Profit Margin(ttm)
-31.82%
Return on Equity(ttm)
--
Return on Invested Capital(ttm)
-542.34%
Return on Assets(ttm)
-20.57%
Income Statement
Revenue(ttm)
169.88M
Revenue Per Share(ttm)
0.78
Gross Profit(ttm)
108.40M
EBITDA(ttm)3
2.77M
Net Income Available to Common(ttm)
-45.99M
Diluted EPS(ttm)
-0.23
Share Statistics
Beta (5Y Monthly)
0.74
52-Week Change
30.14%
S&P 500 52-Week Change
12.74%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
218.18M
Dividend Yield
0.00%
Float4
209.24M
% Held by Insiders
4.10%
% Held by Institutions
33.92%
Balance Sheet
Total Cash(mrq)
34.02M
Total Cash Per Share(mrq)
0.16
Total Debt(mrq)
38.35M
Total Debt/Equity(mrq)
-76.10%
Current Ratio(mrq)
1.52%
Quick Ratio(mrq)
1.21%
Book Value Per Share(mrq)
-0.24
Cash Flow
Operating Cash Flow Per Share(ytd)
-0.17
Free Cash Flow(ytd)
-36.22M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
- 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
- 2 Market Cap is calculated using total shares outstanding and the most recent share price.
- 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
- 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement